Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Growth Horm IGF Res ; 21(2): 57-62, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21237681

RESUMEN

OBJECTIVE: Beta-hydroxy-beta-methylbutyrate (HMß) is a metabolite of leucine widely used for improving sports performance. Although HMß is recognized to promote anabolic or anti-catabolic effects on protein metabolism, the impact of its long-term use on skeletal muscle and/or genes that control the skeletal protein balance is not fully known. This study aimed to investigate whether chronic HMß treatment affects the activity of GH/IGF-I axis and skeletal muscle IGF-I and myostatin mRNA expression. DESIGN: Rats were treated with HMß (320mg/kg BW) or vehicle, by gavage, for 4 weeks, and killed by decapitation. Blood was collected for evaluation of serum insulin, glucose and IGF-I concentrations. Samples of pituitary, liver, extensor digitorum longus (EDL) and soleus muscles were collected for total RNA or protein extraction to evaluate the expression of pituitary growth hormone (GH) gene (mRNA and protein), hepatic insulin-like growth factor I (IGF-I) mRNA, skeletal muscle IGF-I and myostatin mRNA by Northern blotting/real time-PCR, or Western blotting. RESULTS: Chronic HMß treatment increased the content of pituitary GH mRNA and GH, hepatic IGF-I mRNA and serum IGF-I concentration. No changes were detected on skeletal muscle IGF-I and myostatin mRNA expression. However, the HMß-treated rats although normoglycemic, exhibited hyperinsulinemia. CONCLUSIONS: The data presented herein extend the body of evidence on the potential role of HMß-treatment in stimulating GH/IGF-I axis activity. In spite of this effect, HMß supplementation also induces an apparent insulin resistance state which might limit the beneficial aspects of the former results, at least in rats under normal nutritional status and health conditions.


Asunto(s)
Hormona del Crecimiento/metabolismo , Hiperinsulinismo/inducido químicamente , Factor I del Crecimiento Similar a la Insulina/metabolismo , Valeratos/toxicidad , Animales , Hormona del Crecimiento/genética , Hiperinsulinismo/metabolismo , Factor I del Crecimiento Similar a la Insulina/genética , Masculino , Músculo Esquelético/metabolismo , Miostatina/genética , Miostatina/metabolismo , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Valeratos/administración & dosificación
2.
Mol Cell Endocrinol ; 317(1-2): 1-7, 2010 Apr 12.
Artículo en Inglés | MEDLINE | ID: mdl-20015464

RESUMEN

Cytoskeleton controls the stability of transcripts, by mechanisms that involve mRNAs and eEF1A attachment to it. Besides, it plays a key role in protein synthesis and secretion, which seems to be impaired in somatotrophs of hypothyroid rats, whose cytoskeleton is disarranged. This study investigated the: eEF1A and GH mRNA binding to cytoskeleton plus GH mRNA translation rate and GH secretion, in sham-operated and thyroidectomized rats treated with T3 or saline, and killed 30min thereafter. Thyroidectomy reduced: (a) pituitary F-actin content, and eEF1A plus GH mRNA binding to it; (b) GH mRNA recruitment to polysome; and (c) liver IGF-I mRNA expression, indicating that GH mRNA stability and translation rate, as well as GH secretion were impaired. T3 acutely reversed all these changes, which points toward a nongenomic action of T3 on cytoskeleton rearrangement, which might contribute to the increase on GH mRNA translation rate and GH secretion.


Asunto(s)
Hormona del Crecimiento/genética , Hormona del Crecimiento/metabolismo , Hipotiroidismo/genética , Biosíntesis de Proteínas/efectos de los fármacos , Triyodotironina/farmacología , Actinas/metabolismo , Animales , Peso Corporal/efectos de los fármacos , Citoesqueleto/efectos de los fármacos , Citoesqueleto/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Hipotiroidismo/patología , Factor I del Crecimiento Similar a la Insulina/genética , Factor I del Crecimiento Similar a la Insulina/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Tamaño de los Órganos/efectos de los fármacos , Factor 1 de Elongación Peptídica/metabolismo , Hipófisis/efectos de los fármacos , Hipófisis/metabolismo , Hipófisis/patología , Polirribosomas/efectos de los fármacos , Polirribosomas/metabolismo , Unión Proteica/efectos de los fármacos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar
3.
Transplant Proc ; 39(2): 457-9, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17362758

RESUMEN

UNLABELLED: Renal fibrosis is a hallmark of end-stage renal diseases and of chronic allograft nephropathy (CAN). Rapamycin, besides its action through blockade of lymphocyte proliferation, also has antiproliferative, antiviral, and antitumor actions. Its use in clinical in patients with CAN has recently been advocated. OBJECTIVES: Our goal was to evaluate the effect of rapamycin in an established model of renal fibrosis, unilateral ureteral obstruction. MATERIALS AND METHODS: C57BL/6 mice were divided into two groups, treated or not with daily doses of rapamycin (0.2 mg/kg) beginning on day-1. The obstruction was performed as day 0. Blood and kidney tissues were collected at 1, 4, 7, and 14 days after the surgery to quantify bone morphogenic protein (BMP)-7 and transforming growth factor (TGF)-beta mRNA by real time PCR. RESULTS: Daily treatment with rapamycin caused a significant reduction in serum creatinine at day 1 (0.57 +/- 0.03 vs 0.95 +/- 0.15 mg/dL, P = .002) and at day 14 (0.56 +/- 0.04 vs 0.73 +/- 0.07 mg/dL, P = .040). This profile was corroborated by histological morphometric analyses showing less fibrosis at day 14. However, rapamycin surprisingly induced an upregulation of TGF-beta at day 4 (3.05 +/- 0.46 vs 1.85 +/- 0.41, P = .006) and at day 7 (6.33 +/- 0.55 vs 4.97 +/- 0.38, P = .024) with a reduced expression by day 14 (4.03 +/- 1.07 vs 7.89 +/- 0.83, P < .001). Surprisingly, rapamycin also promoted an increment in BMP-7, completely reversing the ratio of TGF-beta to BMP-7, allowing a more protective phenotype. CONCLUSION: Rapamycin slightly ameliorated the renal dysfunction and, at later time points, induced less fibrosis and less decrease in the TGF-beta to BMP-7 ratio.


Asunto(s)
Fibrosis/inducido químicamente , Riñón/patología , Sirolimus/efectos adversos , Animales , Proteína Morfogenética Ósea 7 , Proteínas Morfogenéticas Óseas/genética , Creatinina/sangre , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Inmunosupresores/efectos adversos , Riñón/efectos de los fármacos , Fallo Renal Crónico/patología , Pruebas de Función Renal , Masculino , Ratones , Ratones Endogámicos C57BL , ARN Mensajero/genética , Factor de Crecimiento Transformador beta/genética
4.
Thyroid ; 11(6): 545-50, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11442001

RESUMEN

Myoglobin (Mb) gene expression, Citrate Synthase (CS) and Succinate Dehydrogenase (SDH) activities of Soleus (S) and Extensorum Digitalis Longus (EDL) muscles were studied in intact, thyroidectomized and T3-treated (25 microg/100g, BW, ip, 15 days) rats. The fiber type composition of S muscle was also evaluated and used as control of the T3-induced effects. In the S muscle, the T3 treatment increased the Mb mRNA and protein expression, as well as the CS and SDH activity. These changes occurred parallel to the expected increase in type II (fast) and decrease in type I (slow)-fibers in S muscle. In the hypothyroid state, the Mb mRNA was decreased, while the Mb expression and CS activity tended to decrease. In contrast the SDH activity was increased, probably due to the enhanced motor activity that occurs as a short-term response to the hypothermia induced by hypothyroidism. In the EDL, the alterations were milder than those in S muscle in both thyroid states. These findings show that Mb gene expression is induced by T3. This is concomitant with the enhancement of Krebs Cycle enzyme activities and provides additional evidence that thyroid hormone increases the aerobic potential of skeletal muscles, as well as the speed of muscle contraction.


Asunto(s)
Músculo Esquelético/metabolismo , Mioglobina/metabolismo , Triyodotironina/farmacología , Animales , Citrato (si)-Sintasa/metabolismo , Ciclo del Ácido Cítrico/efectos de los fármacos , Miembro Posterior , Hipertiroidismo/metabolismo , Hipotiroidismo/metabolismo , Masculino , Mitocondrias/enzimología , Músculo Esquelético/efectos de los fármacos , Mioglobina/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Succinato Deshidrogenasa/metabolismo , Dedos del Pie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...